Lilly kept at peer perform by Bear Stearns

Bear Stearns analyst John Boris reiterated Eli Lilly& Co. at peer perform on upside pressure on the stock ahead of the company's research and development day in early December and also in anticipation of Prasugrel results in the first half of 2007. The analyst is encouraged by improvements in U.S. Zyprexa's sequential trends and Cymbalta's market share gains in a reaccelerating antidepressant market. Shares of the Indianapolis pharmaceutical company were down 13 cents, or 0.22%, at $57.78. (NYSE: LLY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.